Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Towards enzyme activated antiprostatic agents.

G B Jones1, M O Mitchell, J S Weinberg

  • 1Department of Chemistry, Northeastern University, Boston, MA 02115, USA. grjones@lynx.neu.edu

Bioorganic & Medicinal Chemistry Letters
|September 15, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cellular Density in Adult Glioma, Estimated with MR Imaging Data and a Machine Learning Algorithm, Has Prognostic Power Approaching World Health Organization Histologic Grading in a Cohort of 1181 Patients.

AJNR. American journal of neuroradiology·2022
Same author

Estimating Local Cellular Density in Glioma Using MR Imaging Data.

AJNR. American journal of neuroradiology·2020
Same author

Imaging-Based Algorithm for the Local Grading of Glioma.

AJNR. American journal of neuroradiology·2020
Same author

New approaches to pyrrolo[2,1-c][1,4]benzodiazepines: synthesis, DNA-binding and cytotoxicity of DC-81.

Tetrahedron·2018
Same author

Determining optimal eluter design by modeling physical dose enhancement in brachytherapy.

Medical physics·2018
Same author

Optimizing the Bioavailability of Subcutaneously Administered Biotherapeutics Through Mechanochemical Drivers.

Pharmaceutical research·2017
Same journal

Discovery of a potent sGC stimulator with once-daily dosing potential for the treatment of hypertension.

Bioorganic & medicinal chemistry letters·2026
Same journal

OracleScreen-LILRB4 (HTS-Oracle v3): machine learning-guided discovery of myeloid immune checkpoint binders validated in patient-derived cells.

Bioorganic & medicinal chemistry letters·2026
Same journal

Rational design and N-terminal acylation of a lactam-cyclized 11-residue antimicrobial peptide for improved antibacterial potency.

Bioorganic & medicinal chemistry letters·2026
Same journal

Rational design, synthesis, and biological evaluation of chalcone hybrids including benzoylpiperazin (phenylacetylpiperazin)-thiophene as anti- Alzheimer's agents.

Bioorganic & medicinal chemistry letters·2026
Same journal

New aminopiperidine-azoles as antifungal agents against Candida albicans with mechanistic insights into the cAMP-PKA pathway.

Bioorganic & medicinal chemistry letters·2026
Same journal

Novel 1H-pyrrole-2,5-dione derivatives as potential anti-diabetic agents: design, synthesis, in vitro, in ovo, and molecular docking studies.

Bioorganic & medicinal chemistry letters·2026
See all related articles

A novel prodrug conjugate was synthesized for activation by prostate specific antigen (PSA) or alpha-chymotrypsin. This system demonstrates selective cancer cell killing in a PSA-secreting cell line.

Area of Science:

  • Biochemistry
  • Medicinal Chemistry
  • Oncology

Background:

  • Prostate specific antigen (PSA) is a biomarker for prostate cancer.
  • Targeted drug delivery systems can improve cancer therapy efficacy.
  • Prodrugs offer a strategy for localized drug activation.

Purpose of the Study:

  • To synthesize a prodrug conjugate activated by PSA.
  • To evaluate the selective cytotoxicity of the prodrug system.

Main Methods:

  • Synthesis of a prodrug conjugate.
  • In vitro enzymatic activation studies using PSA and alpha-chymotrypsin.
  • Cytotoxicity assays on PSA-secreting and non-secreting cell lines.

Main Results:

Related Experiment Videos

  • The synthesized prodrug conjugate was successfully activated by PSA and alpha-chymotrypsin.
  • The prodrug system exhibited selective cytotoxicity against a PSA-secreting cell line.
  • Minimal toxicity was observed in non-PSA-secreting cells.

    • Conclusions:

    • A PSA-activated prodrug conjugate was developed.
    • This prodrug system shows potential for targeted prostate cancer therapy.
    • Enzymatic activation offers a route to selective cancer cell killing.